Streptococcus agalactiae bacteria, responsible for vaginal and urinary tract infections and neonatal infections, including meningitis and sepsis. Optical microscope view.
James Cavallini | BSIP | Universal group of images | Getty’s paintings
Pfizer on Wednesday he said it was experimental Vaccine targeting a potentially fatal bacterial disease Group B streptococcus he got here back strong mid stage clinical trial resultsa promising step because the drug approaches potential approval.
Pfizer is one in all several drugmakers racing to develop the world’s first injection to focus on group B strep, which is linked to almost 150,000 infant deaths around the globe every 12 months, especially in lower-income countries.
related investment news
Food and Drug Administration in September was awarded the title of breakthrough therapy to Pfizer’s vaccine to speed up vaccine development and review.
A single dose of Pfizer’s vaccine generated antibodies that might provide infants with significant protection against the disease data released Wednesday from a phase two clinical trial.
The stab is served pregnant women who pass vaccine-induced antibodies to their fetuses. Certainly one of the corporate’s vaccines for respiratory syncytial virus also uses this maternal vaccination method.
Encouraging results from Pfizer’s Phase 2 trial offer hope that vaccinating moms against the disease, also referred to as GBS, could help prevent 1000’s of infant cases.
The results can even help the corporate plan for Phase 3 clinical trials for the injection, which are often required before the drug is approved by the FDA.
The Bill and Melinda Gates Foundation, which supported the second phase of the study, provided additional assistance A $100 million grant to Pfizer last 12 months, which can fund late-stage research and facilitate delivery of injections to lower-income countries if approved.
GBS risk
GBS disease is attributable to a common and frequently harmless bacteria that many adults carry of their bodies.
However the mother-to-be can pass this bacterium on to her newborn during childbirth, which may cause serious infections in the primary few weeks or months of the infant’s life.
ABOUT 1 out of 4 based on the Centers for Disease Control and Prevention for women, it is a carrier of GBS bacteria.
Infants with GBS infection may experience symptoms including fever and difficulty respiratory.
Some infants may experience invasive GBS infections that cause more serious complications similar to pneumonia, bloodstream infections, and meningitis, or inflammation of the tissues surrounding the brain and spinal cord.
There are 10 different GBS serotypes, meaning different strains of disease-causing bacteria. Pfizer’s vaccine targets the six most outstanding serotypes, which collectively account for 98% of GBS cases worldwide.
Test results and safety
The Pfizer study involved 360 healthy pregnant women in South Africa. Moms were randomly assigned to receive a single injection at three different dose levels, with or with no specific adjuvant, or placebo.
The study found that the Pfizer injection produced strong antibodies against six GBS serotypes within the moms. These antibodies were “successfully transferred” to infants in proportions between 0.4 and 1.3, depending on the dose.
Which means that some infants only received a fraction of the antibodies from their moms, while others received higher levels of antibodies than even their moms.
Pfizer said these levels of antibody transfer are related to a reduced risk of GBS disease. This conclusion was based on a parallel natural history conducted in South Africa.
Based on the study results, the protection profile of each moms and infants seemed to be similar within the vaccine and placebo groups, suggesting that the injection was generally well tolerated in the course of the Phase 2 study.
Post-vaccination maternal reactions were generally mild to moderate and of short duration. Based on the results, between 2% and eight% of participants who received the injection reported a fever, compared with 5% within the placebo group.
About 45% to 70% of pregnant women who received the vaccine had more uncomfortable side effects, similar to headache and vomiting. However the placebo group wasn’t much different, with greater than 60% of mothers-to-be experiencing these uncomfortable side effects.
Roughly 62% to 75% of infants within the vaccinated group and 74% within the placebo group experienced antagonistic events, including upper respiratory tract infections. There have been three infant deaths within the vaccinated group and two within the placebo group.
The authors of the study determined that no antagonistic events or infant deaths were related to the vaccine.
The results come as Pfizer braces for an extra decline in Covid-related sales this 12 months.
Pfizer is also facing a patent cliff or lack of market exclusivity for several blockbuster drugs similar to the cancer drugs Xtandi and Ibrance. By 2030, this is expected to deliver a further blow to Pfizer’s annual revenue.
To counter the sharp decline in sales, the corporate is specializing in a recent drug pipeline and mergers and acquisitions.